| Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. | |
| | |
MedLine Citation:
|
PMID: 22282348 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Standard therapy for older patients with acute myeloid leukemia (AML) has a poor outcome. The authors have designed a combination of clofarabine plus low-dose cytarabine followed by a prolonged consolidation alternating with decitabine. METHODS: Sixty patients with a median age of 70 years (range, 60-81 years) with newly diagnosed AML were included. They received clofarabine 20 mg/m(2) intravenously daily for 5 days plus cytarabine 20 mg subcutaneously twice daily for 10 days. Responding patients continued for up to 17 courses of consolidation therapy including decitabine. RESULTS: Forty of 59 evaluable patients responded (66%). Complete remission rate was 58%. Median relapse-free survival (RFS) was 14.1 (95% confidence interval [CI], 6.9 to not estimable), and median overall survival (OS) was 12.7 months (95% CI, 8.8 to not estimable). Median OS of responding patients (complete response [CR]/CR with platelet count <100 × 109/L) was 24.2 months (95% CI, 17 to not estimable). Compared with a historical group of patients who received clofarabine plus low-dose cytarabine with a shorter consolidation, RFS was not statistically different. Induction mortality was low (7% at 8 weeks) and toxicities manageable. CONCLUSIONS: Clofarabine plus low-dose cytarabine alternating with decitabine in consolidation is active in older patients with newly diagnosed AML. The benefits of a prolonged consolidation remain unproven. |
| | |
Authors:
|
Stefan Faderl; Farhad Ravandi; Xuelin Huang; Xuemei Wang; Elias Jabbour; Guillermo Garcia-Manero; Tapan Kadia; Alessandra Ferrajoli; Marina Konopleva; Gautam Borthakur; Jan Burger; Jennie Feliu; Hagop M Kantarjian |
Related Documents
:
|
6086468 - Uterine sarcomas: a clinicopathologic study, 1965-1981. 22726938 - Radiotherapy alone for stage i-iii low grade follicular lymphoma: long-term outcome and... 22579298 - National survey of the medical treatment status for non-small cell lung cancer (nsclc) ... 22287758 - Improved radiotherapy for primary and secondary liver cancer: stereotactic body radiati... 21789688 - Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therap... 19943208 - Jx-594, a targeted oncolytic poxvirus for the treatment of cancer. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2012-01-26 |
Journal Detail:
|
Title: Cancer Volume: 118 ISSN: 1097-0142 ISO Abbreviation: Cancer Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-09-06 Completed Date: 2012-11-19 Revised Date: 2013-06-03 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 4471-7 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2012 American Cancer Society. |
Affiliation:
|
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. sfaderl@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenine Nucleotides
/
adverse effects,
therapeutic use* Age Factors Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols / adverse effects, therapeutic use* Arabinonucleosides / adverse effects, therapeutic use* Azacitidine / adverse effects, analogs & derivatives*, therapeutic use Consolidation Chemotherapy Cytarabine / adverse effects, therapeutic use* Female Humans Induction Chemotherapy Leukemia, Myeloid, Acute / drug therapy*, mortality Male Middle Aged Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adenine Nucleotides; 0/Arabinonucleosides; 147-94-4/Cytarabine; 320-67-2/Azacitidine; 762RDY0Y2H/clofarabine; 776B62CQ27/decitabine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Allograft Anterior Cruciate Ligament Reconstruction: Indications, Techniques, and Outcomes.
Next Document: Heavy metal pollution across sites affecting the intestinal helminth communities of the Egyptian liz...